How to Achieve Long-Term Survival in Patients with Metastatic Rectal Cancer?
- 3 May 2012
- book chapter
- Published by Springer Nature
- p. 205-216
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II TrialThe Oncologist, 2011
- Improved Survival after Resection of Liver and Lung Colorectal Metastases Compared with Liver-Only Metastases: A Study of 112 Patients with Limited Lung Metastatic DiseaseJournal of the American College of Surgeons, 2011
- Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases.Journal of Clinical Oncology, 2011
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyAnnals of Oncology, 2011
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08Journal of Clinical Oncology, 2011
- "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II studyBMC Cancer, 2010
- The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver MetastasesAnnals of Surgical Oncology, 2009
- Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal MetastasesJournal of Clinical Oncology, 2008
- Liver Histology and Surgical Outcomes After Preoperative Chemotherapy With Fluorouracil Plus Oxaliplatin in Colorectal Cancer Liver MetastasesJournal of Clinical Oncology, 2006
- Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?Journal of Clinical Oncology, 2006